SecBot SecBot

BBNX

Beta Bionics, Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001674632 Healthcare & Medical Devices
$20.51 +1.35 (+7.05%)
Oct 26 4:00 PM ET · prev $19.16
Market cap
$1.0B
Small cap
Consensus
Buy
74% Buy or better · 19 analysts
Median target
$25.00
+22% · range $16.00–30.40
1 year
−13.6%
from $23.75 · Oct 27
30 days
−0.0%
from $20.52
52-week range
$8.86–31.99
−36% from high · low Apr 10
Avg volume 20D
1.02M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$3.9M
0 buyers · 7 sellers · since Feb 27
New fund stakes
0
Q2 2026 13F · 1 exit
Filing reports
17
analyzed by SecBot
SecBot read BEARISH 12 reports · 90 days
Balance 6 bearish · 1 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/12
Strongest BULLISH Beta Bionics disclosed an FDA approval for its iLet bionic pancreas system and related regulatory updates…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • R Apr 21 Beta Bionics reported strong Q1 2026 revenue growth of 57% year-over…
  • S May 21 to May 22 2 days of insider sells: $41.0K by 2 insiders, avg $10.26
  • S Jun 2 to Jun 4 2 days of insider sells: $515.2K by 6 insiders, avg $12.70
  • S Jun 24 to Jun 29 3 days of insider sells: $210.4K by 3 insiders, avg $16.61
  • S Sep 2 to Sep 22 6 days of insider sells: $3.0M by 6 insiders, avg $19.24
  • X Sep 30 Short interest falls 43.0% to 6.05M
  • A Oct 12 Jefferies initiates
  • E Oct 16 M&A: Beta Bionics (BBNX) Alert: Securities Class Action Filed,…

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $3.9M.

  • InstitutionsMIXED

    Q2 2026: 17 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    14 of 19 rate it Buy or better. Median target $25.00 (+22%).

  • TrendRANGE

    7% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
RTW INVESTMENTS, LPTRIM1,500,000$23.5M
BALYASNY ASSET MANAGEMENT L.P.ADD855,682$13.4M
JPMORGAN CHASE & CODOUBLED703,356$12.0M
FARALLON CAPITAL MANAGEMENT, L.L.C.NEAR_EXIT595,000$9.3M
BANK OF AMERICA CORP /DE/DOUBLED546,650$8.6M
GOLDMAN SACHS GROUP INCDOUBLED537,105$8.4M
Trexquant Investment LPDOUBLED494,435$7.7M
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDTRIM409,300$6.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 74% rate it Buy or better
Strong Buy6Buy8Hold5Sell0Strong Sell0
12-month targets · 14 analysts

Price is inside the target range. Median implies +22%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026Jefferies
INITIATE
INITIATEBuy
Sep 24, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Sep 23, 2026Wells Fargo
INITIATE
INITIATEOverweight
Sep 15, 2026B of A Securities
MAINTAIN
MAINTAINNeutral
Sep 15, 2026Truist Securities
REITERATE
REITERATEBuy
Sep 15, 2026Baird
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$3.9M
sold · 7 insiders
DateInsiderTypeValue
Oct 14, 2026
Hopman Mark
Chief Commercial Officer
SELL$13.4K
Oct 1, 2026
Hopman Mark
Chief Commercial Officer
SELL$7.0K
Sep 22, 2026
Jones Christy
Director
SELL$147.9K
Sep 16, 2026
Hopman Mark
Chief Commercial Officer
SELL$619.6K
Sep 16, 2026
Mensinger Mike
Chief Product Officer
SELL$58.3K
Sep 14, 2026
Hopman Mark
Chief Commercial Officer
SELL$12.0K
Sep 9, 2026
Hopman Mark
Chief Commercial Officer
SELL$680.7K
Sep 9, 2026
Hopman Mark
Chief Commercial Officer
SELL$664.6K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.44-$0.52–-$0.40+13.7%$30.2M
Current FY-$1.88-$2.06–-$1.61+0.8%$124.4M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 Earnings calendar
🔒 Fresh data, subscribers only
Oct 14, 2026 Insider
Hopman Mark sold 775 shares
Chief Commercial Officer @ $17.35 ($13.4K)
Oct 7, 2026 SEC
T. Rowe Price Associates, Inc. filed a Schedule 13G disclosing a 16.6% passive stake in Beta Bionics, Inc. as of…
SC 13G — Impact 4/10
Oct 1, 2026 Insider
Hopman Mark sold 370 shares
Chief Commercial Officer @ $18.96 ($7.0K)
Sep 23, 2026 SEC
Three Beta Bionics insiders, including the Chief Commercial Officer, sold a total of $826K in shares over a one-week…
CLUSTER — Impact 4/10
Sep 22, 2026 Insider
Jones Christy sold 6,430 shares
Director @ $23.00 ($147.9K)
Sep 18, 2026 SEC
Five Beta Bionics insiders, including the CEO, CFO, and Chief Commercial Officer, sold a total of $1.09M in…
CLUSTER — Impact 5/10
Sep 17, 2026 Press
Beta Bionics closed a $172.5M underwritten public offering of common stock and pre-funded warrants, including full…
Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 27, 2026
Earnings date
🔒 Fresh data, subscribers only
Oct 26, 2026
Press release
🔒 Fresh data, subscribers only
Oct 24, 2026
Press release
BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit
NEW YORK, Oct. 24, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics…
Oct 23, 2026
Press release
BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action
SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Hagens Berman reminds investors in Beta Bionics, Inc. (NASDAQ: BBNX) of the pending securities class…
Oct 21, 2026
Press release
Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance - Hagens Berman
SAN FRANCISCO, Oct. 21, 2026 /PRNewswire/ -- Hagens Berman reminds investors in Beta Bionics, Inc. (NASDAQ: BBNX) of the pending securities class…

SecBot reports

17 filings · 5 press releases · 3 bullish · 4 bearish · 10 neutral
All BBNX filing & press-release reports (22)